Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 38OTHER 25NETWORK 16INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Erlotinib Hydrochloride 2exatecan 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Familial ependymoma × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT00004212 2012-05-16

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Daiichi Sankyo

Phase 1 Completed
CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Lymphoma, Medulloblastoma, Oligodendroglioma, Recurrence, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡